CDKN1C anticorps (AA 34-64)
-
- Antigène Voir toutes CDKN1C Anticorps
- CDKN1C (Cyclin-Dependent Kinase Inhibitor 1C (p57, Kip2) (CDKN1C))
-
Épitope
- AA 34-64
-
Reactivité
- Humain, Souris
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp CDKN1C est non-conjugé
-
Application
- Western Blotting (WB), Immunofluorescence (IF)
- Specificité
- This CDKN1C antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 34-64 amino acids from the N-terminal region of human CDKN1C.
- Purification
- Protein A purified
- Top Product
- Discover our top product CDKN1C Anticorps primaire
-
-
- Indications d'application
- Approved: IF (1:10 - 1:50), WB (1:1000)
- Commentaires
-
Target Species of Antibody: Human
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- Lot specific
- Buffer
- PBS, 0.09 % sodium azide
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- 4 °C,-20 °C
- Stockage commentaire
- Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.
- Date de péremption
- 6 months
-
- Antigène
- CDKN1C (Cyclin-Dependent Kinase Inhibitor 1C (p57, Kip2) (CDKN1C))
- Autre désignation
- CDKN1C / p57 Kip2 (CDKN1C Produits)
- Synonymes
- anticorps BWCR, anticorps BWS, anticorps KIP2, anticorps WBS, anticorps p57, anticorps p57Kip2, anticorps cb961, anticorps p27Xic1-a, anticorps zgc:86618, anticorps AL024410, anticorps CDKI, anticorps Kip2, anticorps p57(kip2), anticorps p57KIP2, anticorps cyclin dependent kinase inhibitor 1C, anticorps cyclin-dependent kinase inhibitor 1Ca, anticorps cyclin-dependent kinase inhibitor 1C (P57), anticorps cyclin-dependent kinase inhibitor 1C, anticorps CDKN1C, anticorps cdkn1ca, anticorps Cdkn1c
- Sujet
-
Name/Gene ID: CDKN1C
Synonyms: CDKN1C, BWS, KIP2, IMAGE, p57Kip2, p57, p57 KIP2, Beckwith-Wiedemann syndrome, WBS, BWCR - ID gène
- 1028
- UniProt
- P49918
- Pathways
- Cycle Cellulaire, Dopaminergic Neurogenesis
-